cbdMD to buy Twinlab brands, lift revenue ~40%

Rhea-AI Filing Summary

cbdMD, Inc. (YCBD) entered into an Asset Purchase Agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea, through an assignment for the benefit of creditors, subject to ABC Court approval and customary closing conditions. Consideration includes assumption of approximately $1,750,000 of secured debt, issuance of 2,229,805 common shares (equal to 19.9% of outstanding shares on signing, with a target of 19.99% at closing), and assumption of specified liabilities; the stock issued to the secured creditor will be subject to leak-out restrictions.

The agreement provides for reimbursement of cbdMD’s expenses up to $300,000 and a breakup fee equal to 4% of the purchase price under certain termination scenarios. Based on unaudited data, combined trailing-twelve-month revenue to June 2026 is about $30 million, roughly 40% above cbdMD’s standalone revenue. Separately, cbdMD amended its Series B Convertible Preferred Stock designation, reducing the common stock conversion price from $1.00 to $0.60 per share for the 591,207 Series B shares outstanding, increasing potential dilution.

Positive

• Transformational acquisition expected to lift revenue ~40%: Based on unaudited figures, combined trailing-twelve-month revenue to June 2026 is approximately $30 million, about 40% higher than cbdMD’s standalone revenue for the same period, expanding its multi-brand consumer wellness platform.
• Strategic diversification beyond hemp-derived products: Management states the Twinlab brands are expected to reduce revenue concentration in hemp and broaden cbdMD’s presence into supplements, sports nutrition, beauty, weight management, and longevity categories.
• Incremental revenue expected to be positively contributive: The company states the additional revenue from the acquired brands is expected to generate positive contribution after transaction and integration costs.

Negative

• Significant equity dilution from acquisition consideration: cbdMD will issue 2,229,805 common shares, targeting up to 19.99% of outstanding shares at closing, as part of the purchase price, directly diluting existing common shareholders.
• More dilutive terms on existing preferred stock: The Series B Convertible Preferred Stock conversion price was reduced from $1.00 to $0.60 per share for 591,207 outstanding Series B shares, increasing potential common share issuance upon conversion.
• Additional leverage and assumed obligations: The transaction includes assumption of approximately $1,750,000 of secured debt plus specified liabilities, and also introduces a breakup fee of 4% of the purchase price payable in certain termination scenarios.

8-K Event Classification

4 items: 1.01, 5.03, 7.01, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Assumed secured debt: $1,750,000 Common Stock Consideration: 2,229,805 shares Target ownership percentage at closing: 19.99% +6 more

9 metrics

Assumed secured debt $1,750,000 Debt owed to the secured creditor assumed as part of Twinlab asset purchase consideration

Common Stock Consideration 2,229,805 shares Equals 19.9% of cbdMD’s outstanding common shares as of Asset Purchase Agreement signing

Target ownership percentage at closing 19.99% Maximum equity stake represented by Common Stock Consideration if share count increases before closing

Expense reimbursement cap $300,000 Maximum reimbursement of cbdMD’s expenses in connection with the Asset Purchase Agreement

Breakup fee 4% of purchase price Payable under certain termination circumstances of the Asset Purchase Agreement

Combined trailing-twelve-month revenue $30,000,000 Combined unaudited revenue for cbdMD and Twinlab brands for the twelve months ended June 2026

Revenue increase versus standalone 40% Approximate increase of combined unaudited revenue over cbdMD’s standalone revenue for the same period

Series B conversion price $0.60 per share Reduced from $1.00 per share for Series B Convertible Preferred Stock effective September 2, 2026

Series B shares outstanding 591,207 shares Outstanding Series B Convertible Preferred Stock subject to the new $0.60 conversion price

Key Terms

Asset Purchase Agreement, assignment for the benefit of creditors, Series B Convertible Preferred Stock, conversion price, +2 more

6 terms

Asset Purchase Agreement financial

"entered into an Asset Purchase Agreement by and among the Company"

An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.

assignment for the benefit of creditors regulatory

"conducted through an assignment for the benefit of creditors (ABC) proceeding"

Series B Convertible Preferred Stock financial

"designating 1,700,000 shares of the Company’s authorized preferred stock as Series B Convertible Preferred Stock"

Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.

conversion price financial

"reducing the conversion price to $0.60 per share"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

breakup fee financial

"and a breakup fee in an amount equal to 4% of the purchase price"

A breakup fee is a cash payment required when a proposed merger or acquisition is called off, meant to compensate the party that prepared for the deal for its costs and lost opportunity. For investors, the size and presence of a breakup fee signal how committed parties are to completing the deal and can affect the probability of closing and the target’s share price, much like a nonrefundable deposit influences whether an appointment moves forward.

leak-out restrictions financial

"The Common Stock Consideration will be subject to leak-out restrictions"

FAQ

What transaction did cbdMD (YCBD) announce with Twinlab?

cbdMD entered into a definitive Asset Purchase Agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea, through an assignment for the benefit of creditors, subject to court approval and customary closing conditions.

How much is cbdMD (YCBD) paying for the Twinlab assets and in what form?

Consideration includes assumption of approximately $1,750,000 of secured debt, issuance of 2,229,805 shares of common stock (equal to 19.9% of shares outstanding on signing, targeting 19.99% at closing), and assumption of specified liabilities; the stock will be subject to leak-out restrictions.

How will the Twinlab acquisition affect cbdMD (YCBD) revenues?

Based on unaudited information, combined trailing-twelve-month revenue through June 2026 is approximately $30 million, which the company states would represent an increase of about 40% versus cbdMD’s standalone revenue for the same period. This figure is illustrative and not guidance.

What changes did cbdMD (YCBD) make to its Series B Convertible Preferred Stock?

Effective September 2, 2026, cbdMD reduced the Series B conversion price from $1.00 to $0.60 per common share. There are 591,207 Series B shares outstanding, so the lower conversion price increases potential common share issuance upon conversion.

What termination protections and fees are included in cbdMD’s (YCBD) Twinlab agreement?

The Asset Purchase Agreement allows various termination rights and includes reimbursement of cbdMD’s expenses up to $300,000 and a breakup fee equal to 4% of the purchase price, payable under certain circumstances if the agreement is terminated.

Is cbdMD’s (YCBD) Twinlab acquisition already closed?

No. Completion is subject to multiple closing conditions, including that an ABC Court enter a sale order approving the transaction. The company states it expects to complete the transaction in its first fiscal quarter, subject to this approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:30 AM Accepted by SEC EDGAR 09/02/2026 - 07:30 AM Learn about SEC filing dates

false 0001644903 0001644903 2026-09-01 2026-09-01

--09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2026

cbdMD, Inc.

(Exact name of registrant as specified in its charter)

North Carolina		001-38299		47-3414576
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2101 Westinghouse Blvd., Suite A Charlotte, NC 28273

(Address principal executive offices) (Zip code)

Registrant's telephone number, including area code: (704) 445-3060

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	YCBD	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On September 1, 2026, cbdMD, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) by and among the Company, To Be Brands, LLC, a North Carolina limited liability company and wholly owned subsidiary of the Company, Twinlab Consolidated Holdings, Inc., a Nevada corporation (“Twinlab”), the wholly owned direct and indirect subsidiaries of Twinlab set forth in the Asset Purchase Agreement (the “Assignors”), Philip J. Von Kahle, in his capacity as the duly appointed assignee for the benefit of creditors of each of the Assignors under a General Assignment for the Benefit of Creditors dated August 21, 2026 (the “Assignee”), and Akretive Holdings, LLC, a New York limited liability company (the “Secured Creditor”). Pursuant to the Asset Purchase Agreement, the Company will acquire certain assets and property of the Assignors, primarily consisting of stock in certain Twinlab direct and indirect subsidiaries, intellectual property, inventory, receivables, goodwill, and cash exceeding the reasonable fees and expenses of the Assignee. Twinlab is a marketer, distributor, and direct-to-consumer retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty store retailers, online retailers, and websites.

The aggregate consideration for the assets to be acquired consists of: (a) assumption of certain debt owed to the Secured Creditor of approximately $1,750,000 (the “Assumed Debt”); (b) issuance of 2,229,805 shares of the Company’s common stock, par value $0.001 per share, which equals 19.9% of the outstanding shares of the Company’s common stock as of the execution date of the Asset Purchase Agreement (the “Common Stock Consideration”); and (c) assumption of the Assumed Liabilities as set forth in the Asset Purchase Agreement. The Assumed Debt will be secured by the acquired assets. The Common Stock Consideration will be subject to leak-out restrictions following the closing of the Asset Purchase Agreement. If the Company’s total outstanding shares increase prior to the closing of the Asset Purchase Agreement, the Common Stock Consideration will be increased to meet the 19.99% additional share target percentage. Upon closing, the Company will issue the Common Stock Consideration to the Secured Creditor, provided, however, that if stockholder approval is required by the rules or regulations of NYSE American in connection with such issuance, such issuance shall be conditioned upon the receipt of such stockholder approval.

The Asset Purchase Agreement contains customary representations and warranties of the Company and the Assignors and is subject to a number of closing conditions, including, among others, (a) the accuracy of representations and warranties of the parties; (b) material compliance with the obligations of the parties set forth in the Asset Purchase Agreement; and (c) a court of competent jurisdiction (the “ABC Court”) shall have entered a sale order, which shall be in full force and effect and shall not be subject to any stay.

The Asset Purchase Agreement may be terminated, subject to certain exceptions: (a) by the mutual written consent of the parties; (b) by either the Company or the Assignee if: (i) the closing of the Asset Purchase Agreement has not occurred on or before two business days after the order approving the sale becomes a final order; (ii) any law or order is enacted that prohibits or restrains the transactions contemplated by the Asset Purchase Agreement; or the ABC Court enters a final order denying approval of the sale to the Company; (c) by the Company if: (i) the Assignee, Twinlab or the Assignors fail to satisfy certain conditions and obligations of the Asset Purchase Agreement; or (ii) Twinlab or any Assignor materially breaches any covenant, representation or warranty of the Asset Purchase Agreement and fails to cure such material breach; or (d) by the Assignee if: (i) the Company fails to satisfy certain conditions and obligations of the Asset Purchase Agreement; or (ii) the Company materially breaches any covenant, representation or warranty of the Asset Purchase Agreement and fails to cure such material breach. The Asset Purchase Agreement provides for the reimbursement of the Company’s expenses incurred in connection with the Asset Purchase Agreement up to an aggregate amount of $300,000 and a breakup fee in an amount equal to 4% of the purchase price, payable under certain circumstances upon a termination of the Asset Purchase Agreement. Subject to ABC Court approval, the Company expects to complete the Asset Purchase Agreement in the Company’s first fiscal quarter.

The foregoing description of the Asset Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, which is filed as Exhibit 10.1 to this Form 8-K and incorporated herein by reference. The representations and warranties contained in the Asset Purchase Agreement were made only for the purposes of the Asset Purchase Agreement and solely for the benefit of the parties thereto. Those representations and warranties may be subject to important limitations and qualifications agreed to by the contracting parties. Some of those representations and warranties may not be accurate or complete as of any particular date because they are subject to contractual standards of materiality different from that generally applicable to public disclosures to stockholders. Furthermore, the representations and warranties may have been made for the purposes of allocating contractual risk between the parties to such contract or other document instead of establishing these matters as facts, and they may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this Form 8-K. Accordingly, you should not rely upon the representations and warranties in the Asset Purchase Agreement as statements of factual information.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. 

On September 29, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Designation”) designating 1,700,000 shares of the Company’s authorized preferred stock as Series B Convertible Preferred Stock (the “Series B”). Each share of the Series B was initially convertible into common stock at a conversion price of $1.00, subject to anti-dilution and other adjustment rights and preferences as defined in the Certificate of Designation. Effective September 2, 2026, the Company filed an amendment to the Certificate of Designation reducing the conversion price to $0.60 per share. There are currently 591,207 shares of Series B issued and outstanding. The description of the amendment to the Certificate of Designation is not complete and is qualified in its entirety by the full text of the Articles of Amendment to the Certificate of Designation filed herewith as Exhibit 3.1 which is incorporated by reference into this Item 5.03.

Item 7.01. Regulation FD Disclosure.

On September 2, 2026, in connection with the execution of the Asset Purchase Agreement, the Company issued the press release attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information set forth in this Item 7.01 and in the press release attached hereto as Exhibit 99.1, is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit
3.1		Articles of Amendment to the Certificate of Designation of Series B Convertible Preferred Stock effective September 2, 2026
10.1		Asset Purchase Agreement by and among cbdMD, Inc., To Be Brands, LLC, Twinlab Consolidated Holdings, Inc., certain wholly owned subsidiaries of Twinlab Consolidated Holdings, Inc., Philip J. Von Kahle and Akretive Holdings, LLC dated September 1, 2026
99.1		Press Release dated September 2, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	cbdMD, Inc.
Date: September 2, 2026	By:	/s/ T. Ronan Kennedy
		Name: T. Ronan Kennedy
		Title: Chief Executive Officer and Chief Financial Officer

Exhibit 99.1

cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women’s Beauty, Weight Loss and Longevity Wellness

Agreement will add iconic supplement brands to cbdMD’s growing multi-brand consumer wellness platform, anticipated to increase revenues to approximately $30 million.

CHARLOTTE, N.C., September 2, 2026, cbdMD, Inc. (NYSE American: YCBD), a leading consumer wellness company, today announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea. The acquisition is being conducted through an assignment for the benefit of creditors (ABC) proceeding and is subject to court approval and customary closing conditions.

The transaction is expected to give the acquired brands a stable home and provide an orderly path forward for the business’s legacy obligations, allowing the brands, their products, and their customer relationships to continue uninterrupted. For customers, retailers, and distribution partners, it means the products they rely on will remain available and are backed by a company committed to investing in them for the long term.

This transaction is expected to reduce cbdMD’s revenue concentration in the hemp category and mitigate risks associated with the evolving regulatory environment for hemp-derived products. Based on unaudited financial information, the combined unaudited trailing twelve months of revenue ending June 2026 totals approximately $30 million, which would represent an increase of approximately 40% relative to cbdMD’s standalone revenue for the same period. The incremental revenue is expected to generate positive contribution after transaction and integration costs. This combined revenue figure is provided for illustrative purposes only and should not be viewed as indicative of future results.

The transaction marks a significant step in cbdMD’s evolution into a broader multi-brand consumer wellness platform spanning supplements, sports nutrition, longevity, functional wellness, pet wellness, hemp-derived products, and adjacent consumer health categories. As the platform grows beyond its origins in CBD and hemp, the Company expects its identity to evolve to reflect the full breadth of consumer wellness it now serves.

Founded in 1968, Twinlab is one of the most recognized names in legacy supplements and sports nutrition, bringing decades of consumer recognition, category credibility, retail relevance in serving 50,000 retail outlets, including Vitamin Shop and GNC in addition to a strong Amazon presence, and product heritage across vitamins, minerals, active lifestyle, beauty and performance nutrition.

"Twinlab is the kind of brand equity that companies spend decades trying to build," said Ronan Kennedy, CEO of cbdMD. "The brands, distribution channels, and team are highly complementary to what we already operate, and this transaction gives these brands the stability and support they need for their next chapter. We believe there is a significant opportunity to build on cbdMD’s revenue growth by applying our marketing, creative, and ecommerce resources to drive brand awareness and expand direct-to-consumer sales, alongside the strong wholesale and retail presence these brands already have. From the fundamentals of nutrition to the frontier of modern wellness, the combined portfolio is a unique offering in consumer wellness."

"cbdMD is the right home for these brands," said Anthony Zolezzi, Chief Executive Officer of Twinlab. "Together, we will bring a uniquely complete wellness portfolio spanning foundational vitamins, minerals, and nutrition through botanicals, beauty, longevity, functional mushrooms, cannabinoids, and the emerging breakthroughs defining where this industry is headed. We believe no other company can serve consumers across more needs, more moments, and more stages of life than we now can together. This combination will pair decades of heritage and category credibility with a modern, marketing-driven platform and the resources to reintroduce these products to a new generation of consumers. It positions the brands, and the people behind them, for a strong future.”

Upon closing of the acquisition the acquired portfolio will expand cbdMD’s reach into additional consumer need states, including daily wellness, active lifestyle, weight management, longevity, recovery, beauty and functional supplementation. Reserveage brings premium longevity, resveratrol, collagen, and beauty-from-within positioning; Metabolife will bring established weight management brand recognition products.

The agreement follows cbdMD’s earlier acquisition and integration of Bluebird Botanicals and reflects the Company’s continued strategy of building a portfolio of trusted wellness brands that benefit from shared infrastructure, operational alignment, product innovation, and modern commerce execution.

In connection with entering into the agreement, cbdMD has filed a Current Report on Form 8-K with the Securities and Exchange Commission, which includes additional details regarding the transaction and conditions for closing.

About cbdMD, Inc.
cbdMD, Inc. is a consumer wellness company focused on building a multi-brand platform across CBD, hemp-derived wellness, pet wellness, botanical wellness, supplements, longevity, functional wellness, and related consumer health categories. The Company’s portfolio includes cbdMD, Paw CBD, Oasis, Bluebird Botanicals.  The Company is focused on quality, transparency, compliance, consumer trust, product innovation, ecommerce, wholesale, retail support, and the development of a broader wellness platform serving multiple consumer needs. For more information, visit www.cbdmd.com.

About Twinlab

Founded in 1968, Twinlab is a heritage leader in nutritional supplements and sports nutrition, with a decades-long reputation for quality and innovation across vitamins, minerals, amino acids, and performance nutrition. The Twinlab family of brands includes Reserveage, a premium longevity and beauty-from-within brand known for its resveratrol, collagen, and healthy-aging products; Metabolife, a recognized name in weight management and Rip Fuel for performance Sports. Together, these brands have built lasting consumer trust and broad distribution across retail, wholesale, and ecommerce channels. 

Forward-Looking Statements
 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements regarding the proposed acquisition, expected revenues, revenue increases, the ability to obtain court approval and complete the transaction, integration plans, brand portfolio development, product availability, and ecommerce. These statements are based on management’s current expectations, estimates, and projections and are subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Such risks include, but are not limited to, court approval of the ABC and complete the transaction on the anticipated terms or timeline, satisfy closing conditions, successfully integrate acquired assets and brands, retain key employees and business relationships, maintain wholesale and retail relationships, execute ecommerce and marketplace strategies, develop new product categories, achieve anticipated operational efficiencies and cost savings, manage costs and capital requirements, maintain regulatory compliance across all product categories, access capital on favorable terms, the risk that the unaudited financial information regarding the acquired brands is inaccurate or that audited financial statements meeting the requirements of Regulation S-X cannot be timely obtained, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contacts

Investors:

cbdMD, Inc.

Ronan Kennedy

Chief Executive Officer and Chief Financial Officer

IR@cbdmd.com

(704) 445-3064

Filing Exhibits & Attachments

7 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 14.9 KB

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 307.0 KB

Other Documents

• EX-3.1 EXHIBIT 3.1 7.0 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.7 KB